Login to Your Account



Clinic Roundup


Friday, November 30, 2012
• Cytokinetics Inc., of South San Francisco, opened enrollment of the third and final cohort in its ATOMIC-AHF Phase IIb trial of omecamtiv mecarbil in left ventricular systolic dysfunction in patients hospitalized for heart failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription